dupilumab · Dupixent

Monoclonal antibody

Also known as REGN668

Approvedregulatory verdict

Evidence outlook

Approved: Asthma, Atopic Dermatitis, Chronic Obstructive Pulmonary Disease, Chronic Spontaneous Urticaria, Prurigo Nodularis, Eosinophilic Esophagitis

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (7)
US
  • Allergic Fungal Rhinosinusitis: DUPIXENT for the treatment of adult and pediatric patients aged 6 years and older with allergic fungal rhinosinusitis (AFRS) who have a history of sino-nasal surgeryOutside this platform's coverageajmc.com
  • Treatment of adult and pediatric patients aged 6 years and older with allergic fungal rhinosinusitis (AFRS) who have a history of sino-nasal surgeryOutside this platform's coverageFDA label
  • Chronic rhinosinusitis with nasal polyps, eosinophilic oesophagitis, prurigo nodularis, chronic spontaneous urticaria, and bullous pemphigoidFDA label
Product first approved 2017
CN
  • Dupixent as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease (COPD) characterized by raised blood eosinophils
Product first approved 2024sanofi.com
JP
  • Treatment of atopic dermatitis in patients who have not responded sufficiently to conventional treatments
Product first approved 2018PMDA
CA
  • Atopic Dermatitis DUPIXENT (dupilumab injection) is indicated for the treatment of patients aged 6 months and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids. Asthma DUPIXENT is indicated as an add-on maintenance treatment in patients aged 6 years and older with severe asthma with a type 2/eosinophilic phenotype or oral corticosteroid-dependent asthma. DUPIXENT is not indicated for relief of acute bronchospasm...
Product first approved 2017Health Canada
EU
  • Atopic dermatitis Adults and adolescents Dupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. Children 6 months to 11 years of age Dupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. Asthma Adults and adolescents Dupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood...
Product first approved 2017EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (46)
Asthma
NCT07309614 · Université de Sherbrooke
2026-01-29 – 2030-01 · Asthma Control
What this study did
NCT06191315 · Sanofi
2024-01-03 – 2028-12-21 · Wheezing, Asthma
What this study did
NCT06461949 · National Institute on Deafness and Other Communication Disorders (NIDCD)
2024-07-17 – 2024-07-17 · Allergic Fungal Rhinosinusitis (AFRS), Chronic Rhinosinusitis (CRS), Asthma, Nasal Polyps
What this study did
NCT03884842 · McMaster University
2019-07-01 – 2023-01-17 · Asthma
What this study did
NCT03620747 · Sanofi
2018-08-30 – 2022-02-18 · Asthma
What this study did
Atopic Dermatitis
NCT07919899 · Sanofi
2026-11-30 – 2028-07-25 · Dermatitis Atopic
What this study did
NCT06389136 · AbbVie
2024-06-14 – 2027-05 · Atopic Dermatitis
What this study did
NCT02612454 · Regeneron Pharmaceuticals
2015-10-15 – 2026-10-09 · Atopic Dermatitis
What this study did
NCT04678882 · Sanofi
2021-01-15 – 2023-10-28 · Atopic Dermatitis
What this study did
NCT03738397 · AbbVie
2019-02-21 – 2020-12-09 · Atopic Dermatitis
What this study did
NCT03912259 · Sanofi
2018-12-19 – 2020-02-14 · Atopic Dermatitis
What this study did
Chronic Obstructive Pulmonary Disease
Chronic Spontaneous Urticaria
Eosinophilic Esophagitis
NCT07112378 · Regeneron Pharmaceuticals
2025-11-10 – 2028-10-09 · Eosinophilic Esophagitis (EoE)
What this study did
Prurigo Nodularis
NCT06293053 · Sanofi
2024-05-15 – 2027-11-03 · Prurigo Nodularis
What this study did
Other / comorbidity
NCT04684524 · Sanofi
2020-12-01 – 2025-03-07 · Allergic Fungal Rhinosinusitis
What this study did
NCT05878093 · Sanofi
2023-05-16 – 2024-11-28 · Chronic Rhinosinusitis With Nasal Polyps
What this study did
NCT05545072 · Emory University
2023-10-26 – 2024-07-10 · Allergic Fungal Rhinosinusitis
What this study did
NCT02898454 · Sanofi
2016-11-28 – 2018-11-16 · Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP)
What this study did
NCT02912468 · Sanofi
2016-12-05 – 2018-07-05 · Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP)
What this study did
Phase 2/3 (4)
Atopic Dermatitis
Other / comorbidity
NCT05535738 · Wei-Che Ko
2022-11-15 – 2027-12-31 · Skin Inflammation, Allergic Contact Dermatitis
What this study did
NCT04206553 · Regeneron Pharmaceuticals
2020-10-28 – 2025-01-05 · Bullous Pemphigoid
What this study did
NCT04244006 · University Hospital, Toulouse
2020-07-23 – 2022-11-15 · Netherton Syndrome
What this study did
Phase 2 (51)
Asthma
NCT05720325 · The University of Texas Health Science Center at San Antonio
2023-03-29 – 2027-11-01 · Asthma, Allergic
What this study did
NCT05347771 · National Institute of Allergy and Infectious Diseases (NIAID)
2022-05-04 – 2027-03-15 · Asthma
What this study did
NCT05575037 · Brigham and Women's Hospital
2023-08-01 – 2026-12-30 · Nasal Polyps, Asthma, Aspirin-Induced, Aspirin-Exacerbated Respiratory Disease, Aspirin-Sensitive Asthma With Nasal Polyps
What this study did
NCT03387852 · Sanofi
2018-03-12 – 2019-08-07 · Asthma
What this study did
NCT02573233 · Sanofi
2016-01-27 – 2018-01-03 · Asthma
What this study did
NCT01312961 · Sanofi
2011-03 – 2012-10 · Asthma
What this study did
Atopic Dermatitis
NCT03359356 · Icahn School of Medicine at Mount Sinai
2018-01-09 – 2020-12-17 · Alopecia Areata
What this study did
NCT03736967 · Regeneron Pharmaceuticals
2018-11-12 – 2020-07-28 · Atopic Dermatitis
What this study did
NCT02407756 · Regeneron Pharmaceuticals
2015-03-31 – 2016-03-31 · Atopic Dermatitis
What this study did
NCT02210780 · Regeneron Pharmaceuticals
2014-08-05 – 2015-09-15 · Atopic Dermatitis
What this study did
NCT01979016 · Regeneron Pharmaceuticals
2013-12-31 – 2015-01-31 · Atopic Dermatitis (AD)
What this study did
NCT01859988 · Regeneron Pharmaceuticals
2013-05 – 2014-09 · Atopic Dermatitis
What this study did
NCT01548404 · Regeneron Pharmaceuticals
2012-04 – 2013-06 · Atopic Dermatitis
What this study did
Chronic Spontaneous Urticaria
NCT03749135 · Charite University, Berlin, Germany
2018-11-12 – 2021-07-07 · Chronic Spontaneous Urticaria, Recurrent Angioedema
What this study did
Eosinophilic Esophagitis
NCT06705387 · University of Colorado, Denver
2024-12-23 – 2027-03 · Eosinophilic Esophagitis
What this study did
NCT02379052 · Regeneron Pharmaceuticals
2015-05-12 – 2017-07-10 · Eosinophilic Esophagitis
What this study did
Other / comorbidity
NCT05866562 · Icahn School of Medicine at Mount Sinai
2024-07-11 – 2029-04-30 · Alopecia Areata
What this study did
NCT07908563 · Icahn School of Medicine at Mount Sinai
2026-08-27 – 2028-12 · Major Depressive Disorder
What this study did
NCT05551793 · Emma Guttman
2023-04-10 – 2028-10-31 · Alopecia Areata
What this study did
NCT07091175 · National University Hospital, Singapore
2025-11-27 – 2028-02-28 · Nephrotic Syndrome in Children, Nephrotic Syndrome Steroid-Dependent
What this study did
NCT06226610 · Akron Children's Hospital
2024-11-21 – 2027-12-31 · Pruritis
What this study did
NCT06477653 · National Institute of Allergy and Infectious Diseases (NIAID)
2025-02-05 – 2027-03-30 · Hypereosinophilic Syndrome
What this study did
NCT04600362 · Technical University of Munich
2021-03-30 – 2027-01-31 · Nummular Eczema
What this study did
NCT05831176 · Regeneron Pharmaceuticals
2023-05-03 – 2026-11-25 · Eosinophilic Gastritis (EoG), Eosinophilic Duodenitis (EoD), Eosinophilic Gastrointestinal Disease (EGID), Eosinophilic Gastroenteritis
What this study did
NCT05031455 · Scripps Clinic
2024-03-25 – 2026-04-20 · Aspirin-exacerbated Respiratory Disease
What this study did
NCT04362501 · Johns Hopkins University
2020-10-15 – 2025-09-30 · Chronic Sinusitis
What this study did
NCT04430179 · University of South Florida
2020-12-17 – 2025-07 · Severe Eosinophilic Chronic Sinusitis Without Nasal Polyposis
What this study did
NCT05128383 · Beth Israel Deaconess Medical Center
2023-01-13 – 2025-06-10 · Keloid
What this study did
NCT03679676 · Stanford University
2020-02-05 – 2025-05-02 · Hypersensitivity, Food Allergy, Hypersensitivity, Food, Peanut Hypersensitivity, Peanut Allergy
What this study did
NCT04148352 · Andrew J Long, PharmD
2021-10-18 – 2025-02-25 · Allergies Food Milk
What this study did
NCT04502966 · National Institute of Allergy and Infectious Diseases (NIAID)
2020-11-05 – 2025-02-20 · Allergic Rhinoconjunctivitis, Grass Pollen Allergy
What this study did
NCT04296864 · Andover Eye Associates
2020-02-10 – 2025-01 · Atopic Keratoconjunctivitis
What this study did
NCT03678545 · Children's Hospital Medical Center, Cincinnati
2021-05-15 – 2024-11-13 · Eosinophilic Gastritis, Eosinophilic Gastroenteritis
What this study did
NCT04256759 · Mayo Clinic
2020-09-01 – 2024-09-06 · Pruritus
What this study did
NCT05967884 · Ottawa Hospital Research Institute
2023-08-04 – 2024-08-01 · Breast Cancer
What this study did
NCT04442269 · Regeneron Pharmaceuticals
2020-09-15 – 2024-02-09 · Allergic Bronchopulmonary Aspergillosis
What this study did
NCT04678856 · Sanofi
2020-12-02 – 2024-01-29 · Chronic Rhinosinusitis Without Nasal Polyps, Sinusitis, Chronic Sinusitis, Sinus Disorder, Respiratory Disorder
What this study did
NCT03861455 · University Hospital, Toulouse
2019-07-15 – 2023-12-20 · Chronic Hand Eczema
What this study did
NCT04200755 · University of Cologne
2020-05-19 – 2023-11-30 · Localized Scleroderma
What this study did
NCT04920916 · University of Virginia
2021-05-25 – 2023-04-18 · COVID-19
What this study did
NCT03749148 · Charite University, Berlin, Germany
2018-12-10 – 2023-02-28 · Cholinergic Urticaria
What this study did
NCT04512339 · University Medical Center Groningen
2020-08-01 – 2022-08 · Hand Eczema
What this study did
NCT03682770 · Regeneron Pharmaceuticals
2018-10-03 – 2021-07-23 · Peanut Allergy
What this study did
NCT03793608 · Regeneron Pharmaceuticals
2019-03-12 – 2021-05-12 · Peanut Allergy
What this study did
NCT03886493 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2019-08-28 – 2020-10-06 · Prostate Cancer
What this study did
NCT03595488 · Rochester General Hospital
2018-09-05 – 2019-12-11 · Aspirin-exacerbated Respiratory Disease
What this study did
NCT03558997 · Regeneron Pharmaceuticals
2018-06-07 – 2019-06-13 · Allergic Rhinitis
What this study did
Phase 1/2 (3)
Other / comorbidity
NCT07277322 · Dan Feng
2026-09-01 – 2030-12-31 · Metastatic Colorectal Cancer, Liver Metastases
What this study did
Dupilumab_Metastatic NSCLCactive not recruiting
NCT05013450 · Thomas Marron
2021-09-10 – 2030-09-18 · Metastatic Non-small Cell Lung Cancer
What this study did
NCT06088771 · Icahn School of Medicine at Mount Sinai
2024-10-09 – 2027-07-01 · Non-Small Cell Lung Cancer
What this study did
Phase 1 (18)
Asthma
NCT03112577 · Regeneron Pharmaceuticals
2017-06-15 – 2019-12-09 · Asthma, Allergic
What this study did
Atopic Dermatitis
NCT05372003 · Mayo Clinic
2022-08-09 – 2024-02-23 · Atopic Dermatitis
What this study did
NCT03050151 · Regeneron Pharmaceuticals
2017-02-28 – 2018-02-12 · Atopic Disorders, Eczema, Atopic
What this study did
NCT02647086 · Regeneron Pharmaceuticals
2015-12 – 2016-07 · Atopic Dermatitis
What this study did
NCT01259323 · Regeneron Pharmaceuticals
2010-12 – 2012-07 · Dermatitis
What this study did
NCT01385657 · Regeneron Pharmaceuticals
2011-07-31 – 2012-03-31 · Atopic Dermatitis
What this study did
Eosinophilic Esophagitis
NCT07358234 · Mayo Clinic
2026-02-04 – 2027-12 · Eosinophilic Esophagitis (EoE)
What this study did
Other / comorbidity
NCT05649098 · Northwestern University
2023-06-12 – 2032-06-01 · Skin Diseases
What this study did
NCT06637306 · Rima Patel
2025-03-05 – 2027-03-10 · Locally Advanced Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer
What this study did
NCT03675022 · Brigham and Women's Hospital
2018-08-15 – 2022-07-01 · Sleep Apnea, Rhinosinusitis Chronic
What this study did
NCT05976386 · Sanofi
2021-06-08 – 2021-09-24 · Healthy Volunteers
What this study did
NCT05976373 · Sanofi
2015-01-05 – 2015-03-30 · Healthy Volunteers
What this study did
NCT05976360 · Sanofi
2014-11-02 – 2015-01-17 · Healthy Volunteer
What this study did
NCT01537653 · Sanofi
2012-03 – 2012-10 · Healthy
What this study did
NCT01537640 · Sanofi
2012-02 – 2012-07 · Healthy
What this study did
NCT01484600 · Regeneron Pharmaceuticals
2011-12 – 2012-02 · Healthy
What this study did
NCT01015027 · Regeneron Pharmaceuticals
2009-10 – 2010-07 · Healthy
What this study did
Phase 4 (57)
Asthma
NCT06818019 · University Hospital, Toulouse
2025-12-15 – 2029-12-31 · Severe Asthma
What this study did
NCT04743791 · Sally E. Wenzel MD
2022-10-17 – 2028-06 · Asthma
What this study did
NCT06385236 · University of California, San Diego
2024-02-19 – 2028-01-31 · Moderate to Severe Asthma
What this study did
NCT03694158 · Boston Children's Hospital
2021-09-08 – 2027-03 · Asthma
What this study did
NCT04380038 · University of Virginia
2022-05-01 – 2026-12-31 · Asthma
What this study did
NCT05942222 · Copenhagen University Hospital, Rigshospitalet
2023-04-27 – 2026-05-01 · Chronic Rhinosinusitis With Nasal Polyps, Asthma; Eosinophilic, Eosinophilia
What this study did
NCT06556264 · Dr. Andrew Thamboo, MD
2024-08 – 2025-12 · Chronic Rhinosinusitis With Nasal Polyps, Asthma
What this study did
NCT04998604 · Sanofi
2021-09-27 – 2024-12-27 · Chronic Rhinosinusitis With Nasal Polyps, Asthma
What this study did
NCT04203797 · Regeneron Pharmaceuticals
2020-07-16 – 2023-07-15 · Asthma
What this study did
NCT05036733 · University of Michigan
2022-02-22 – 2023-06-29 · Asthma
What this study did
Atopic Dermatitis
NCT07905547 · Sanofi
2026-10-28 – 2028-08-02 · Atopic Dermatitis
What this study did
NCT05858619 · University of California, San Francisco
2023-02-01 – 2028-02-01 · Atopic Dermatitis
What this study did
NCT07187089 · Regeneron Pharmaceuticals
2025-11-11 – 2028-01-05 · Severe Atopic Dermatitis (AD)
What this study did
NCT05268107 · University of Michigan
2023-01-25 – 2028-01 · Atopic Dermatitis
What this study did
NCT05042258 · Northwestern University
2024-08-12 – 2027-06 · Atopic Dermatitis, Sleep Disturbance
What this study did
NCT05983068 · Sanofi
2024-02-22 – 2027-05-19 · Dermatitis Atopic
What this study did
NCT06004986 · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
2023-08-14 – 2026-12-31 · Atopic Dermatitis, Atopic Dermatitis Eczema
What this study did
NCT05642208 · Nantes University Hospital
2023-03-08 – 2026-08-27 · Atopic Dermatitis, Eczema, Atopic
What this study did
NCT06116526 · Johns Hopkins University
2024-04-01 – 2026-07-18 · Atopic Dermatitis
What this study did
NCT05436535 · National Institute of Allergy and Infectious Diseases (NIAID)
2022-11-21 – 2025-10-24 · Atopic Dermatitis
What this study did
NCT05285839 · Psoriasis Treatment Center of Central New Jersey
2022-04-19 – 2024-12-15 · Atopic Dermatitis
What this study did
NCT05590585 · Regeneron Pharmaceuticals
2023-01-11 – 2024-11-14 · Moderate-to-Severe Atopic Dermatitis, Atopic Eczema
What this study did
NCT05680298 · Sanofi
2023-02-22 – 2024-03-15 · Atopic Dermatitis
What this study did
NCT05265234 · OptiSkin Medical
2022-03-01 – 2024-03-01 · Eczema, Atopic Dermatitis
What this study did
NCT05624112 · Sanofi
2022-11-25 – 2024-01-25 · Atopic Dermatitis, Dermatitis Atopic
What this study did
NCT04895423 · National Medical Research Center for Children's Health, Russian Federation
2021-11-25 – 2023-07-25 · Atopic Dermatitis
What this study did
NCT03293030 · University of California, San Francisco
2018-10-22 – 2023-02-23 · Atopic Dermatitis, Atopic Dermatitis Eczema, Eczema, Atopic Dermatitis and Related Conditions
What this study did
NCT03667014 · University of California, San Francisco
2018-11-01 – 2022-12-15 · Atopic Dermatitis, Atopic Dermatitis Eczema
What this study did
NCT04718870 · Sanofi
2021-02-19 – 2022-11-30 · Dermatitis Atopic
What this study did
NCT04358224 · Jonathan A. Bernstein, MD
2020-09-01 – 2022-11-18 · Atopic Dermatitis, Eczema
What this study did
NCT04823130 · Sanofi
2021-04-22 – 2022-08-30 · Dermatitis Atopic
What this study did
NCT04033367 · Sanofi
2019-08-22 – 2021-10-06 · Atopic Dermatitis
What this study did
NCT04447417 · Sanofi
2020-07-16 – 2021-06-17 · Atopic Dermatitis
What this study did
NCT04520308 · Eric Simpson
2020-09-01 – 2021-03-31 · Atopic Dermatitis, AD, Eczema
What this study did
NCT03389893 · National Institute of Allergy and Infectious Diseases (NIAID)
2018-07-25 – 2020-09-09 · Atopic Dermatitis (AD)
What this study did
Chronic Obstructive Pulmonary Disease
NCT07053423 · Sanofi
2025-09-22 – 2029-02-02 · Chronic Obstructive Pulmonary Disease
What this study did
Eosinophilic Esophagitis
NCT06352073 · University of North Carolina, Chapel Hill
2024-05-16 – 2026-12 · Eosinophilic Esophagitis, EoE
What this study did
NCT06665971 · University of California, San Diego
2024-11-10 – 2026-11-14 · Eosinophilic Esophagitis (EoE)
What this study did
NCT05247866 · Children's Hospital of Philadelphia
2022-06-16 – 2025-01-21 · Eosinophilic Esophagitis
What this study did
Other / comorbidity
NCT06188871 · University of Rochester
2024-06-01 – 2027-06-01 · Chronic Rhinosinusitis With Nasal Polyps
What this study did
NCT03935971 · Brigham and Women's Hospital
2019-12-18 – 2027-03-31 · Allergic Contact Dermatitis
What this study did
NCT05094570 · University of Virginia
2022-09-01 – 2026-12-31 · Nasal Polyps, Staphylococcus Aureus
What this study did
NCT04869436 · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
2021-07-19 – 2026-09-16 · Chronic Rhinosinusitis With Nasal Polyps, Olfactory Disorder
What this study did
NCT06750471 · Madigan Army Medical Center
2021-10-14 – 2025-12 · Nasal Polyps, Sinusitis, Chronic Disease
What this study did
Early phase / not applicable (6)
Atopic Dermatitis
NCT04878770 · Erasmus Medical Center
2021-08-16 – 2025-01-01 · Dermatitis, Atopic
What this study did
NCT06509243 · Medical University of Silesia
2023-02-10 – 2024-04-10 · Atopic Dermatitis
What this study did
NCT03983460 · Association pour la Recherche Clinique et Immunologique
2020-03-09 – 2021-09 · Atopic Dermatitis
What this study did
NCT04066998 · Centre Hospitalier Universitaire de Besancon
2019-12 – 2021-08 · Conjunctival Diseases, Atopic Dermatitis, Side Effect
What this study did
Other / comorbidity
NCT06501807 · University Hospital, Lille
2024-07-11 – 2035-01-02 · Rhinosinusitis Chronic, Nasal Polyps
What this study did
NCT06743581 · Centre hospitalier de l'Université de Montréal (CHUM)
2025-08-19 – 2030-02 · Non-Small Cell Lung Cancer, Immunotherapy, Neoadjuvant Therapy
What this study did
Used as active comparator (22)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (8)
Atopic Dermatitis
NCT07783425 · Pfizer
2026-08-24 – 2029-06-15 · Atopic Dermatitis
What this study did
NCT07754786 · Innovent Biologics (Suzhou) Co. Ltd.
2026-09-15 – 2028-08-26 · Atopic Dermatitis
What this study did
NCT06884891 · Qilu Pharmaceutical Co., Ltd.
2025-04 – 2028-04 · Atopic Dermatitis
What this study did
NCT07386743 · Jiangsu Genscend Biopharmaceutical Co., Ltd
2026-01-29 – 2028-01 · Atopic Dermatitis (AD)
What this study did
NCT04345367 · Pfizer
2020-06-11 – 2021-07-13 · Atopic Dermatitis
What this study did
NCT03720470 · Pfizer
2018-10-29 – 2020-03-06 · Dermatitis, Dermatitis, Atopic, Eczema, Skin Diseases, Skin Diseases, Genetic, Genetic Diseases, Inborn, Skin Diseases, Eczematous, Hypersensitivity, Hypersensitivity, Immediate, Immune System Diseases
What this study did
Chronic Spontaneous Urticaria
NCT06868212 · Novartis Pharmaceuticals
2025-07-11 – 2027-05-17 · Chronic Spontaneous Urticaria (CSU)
What this study did
Phase 2 (5)
Atopic Dermatitis
NCT07399067 · Innovent Biologics (Suzhou) Co. Ltd.
2026-02-06 – 2027-05-27 · Atopic Dermatitis
What this study did
NCT07330934 · Innovent Biologics (Suzhou) Co. Ltd.
2025-12-31 – 2026-08-18 · Atopic Dermatitis
What this study did
NCT06881251 · Janssen Research & Development, LLC
2025-02-26 – 2026-04-07 · Dermatitis, Atopic
What this study did
NCT05470114 · LEO Pharma
2022-05-19 – 2023-10-09 · Atopic Dermatitis
What this study did
NCT04791319 · Janssen Research & Development, LLC
2021-05-03 – 2022-03-31 · Dermatitis, Atopic
What this study did
Phase 1 (8)
Atopic Dermatitis
NCT07027527 · Apogee Therapeutics, Inc.
2025-06-04 – 2027-12 · Atopic Dermatitis
What this study did
NCT07358156 · Chong Kun Dang Pharmaceutical
2026-02-09 – 2026-11-16 · Atopic Dermatitis
What this study did
NCT07411755 · Jiangsu Genscend Biopharmaceutical Co., Ltd
2026-03-05 – 2026-08-24 · Atopic Dermatitis (AD)
What this study did
NCT06193434 · Innovent Biologics (Suzhou) Co. Ltd.
2024-01-05 – 2025-08-20 · Healthy Participants, Atopic Dermatitis Patients
What this study did
NCT06614907 · Qilu Pharmaceutical Co., Ltd.
2024-08-31 – 2024-12-27 · Atopic Dermatitis
What this study did
Other / comorbidity
NCT07791342 · Mabwell (Shanghai) Bioscience Co., Ltd.
2026-04-22 – 2026-08-17 · Healthy Participants
What this study did
NCT07334496 · Gan & Lee Pharmaceuticals.
2026-03-09 – 2026-07-17 · Biosimilarity
What this study did
NCT07502534 · Innovent Biologics (Suzhou) Co. Ltd.
2026-04-24 – 2026-07-07 · Healthy Volunteers
What this study did
Phase 4 (1)
Other / comorbidity
NCT07268313 · Copenhagen University Hospital, Rigshospitalet
2025-04-03 – 2027-06-01 · Nasal Polyps
What this study did
Studied as part of a combination product (1)

Studies of a fixed-dose combination that contains this drug. The combination is the product under test, so these are that product's evidence rather than this one's; the link is kept because the drug really was administered.

Phase 4 (1)
Atopic Dermatitis
NCT07352566 · University of California, San Francisco
2026-08-01 – 2030-06-01 · Psoriasis, Atopic Dermatitis
What this study did
Appears in other studies (2)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 1 (1)
Other / comorbidity
NCT06369467 · Regeneron Pharmaceuticals
2024-05-17 – 2027-08-31 · Food Allergy
What this study did
Phase 4 (1)
Atopic Dermatitis
NCT06465732 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2025-01 – 2026-07 · Atopic Dermatitis
What this study did

Competitive landscape

This mechanism is crowded: 10 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Atopic Dermatitis: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Dupilumab (Dupixent): this drugApprovedMonoclonal antibodyIL-4R-alphaWeak signal
NCT04417894: Percentage of Participants With Hand and Foot Investigator Global Assessment (IGA) 0 or 1 at Week 16 (At week 16): Dupilumab Q2W 40.3% vs Matching Placebo 16.7%
NCT03345914: Percentage of Participants With Investigator's Global Assessment (IGA) 0 or 1 at Week 16 (Week 16): Dupilumab 300 mg Q4W + TCS 32.8% | Dupilumab 100 mg or 200 mg Q2W + TCS 29.5% vs Placebo + TCS 11.4%
Abrocitinib (Cibinqo)ApprovedSmall moleculeJAK1Reliable signal
NCT04345367: Percentage of Participants Achieving Greater Than or Equal to (>=) 4 Points Improvement in Peak Pruritus Numerical Rating Scale (PP-NRS4) From Baseline at Week 2 (Week 2): Abrocitinib 200 mg QD 48.2% (95% CI 43 to 53.4) vs Dupilumab 300 mg Q2W 25.5% (95% CI 21.1 to 30)
NCT03349060: Percentage of Participants Achieving Investigator's Global Assessment (IGA) Response of Clear (0) or Almost Clear (1) and Greater Than or Equal to 2 Points Improvement From Baseline at Week 12 (Baseline, Week 12): PF-04965842 100 mg 23.7% | PF-04965842 200 mg 43.8% vs Placebo 7.9%
Crisaborole (Eucrisa)ApprovedSmall moleculePDE4Reliable signal
NCT02118766: Percentage of Participants Who Achieved Treatment Success Based on Investigator's Static Global Assessment (ISGA) at Day 29 (Day 29): AN2728 Topical Ointment, 2 Percent 32.8% vs AN2728 Topical Ointment, Vehicle 25.4%
NCT02118792: Percentage of Participants Who Achieved Success in Investigator's Static Global Assessment (ISGA) Score at Day 29 (Day 29): AN2728 Ointment, 2 Percent (%) 31.4% vs AN2728 Ointment, Vehicle 18%
Difamilast (Moizerto / Adquey)ApprovedSmall moleculePDE4Partial signal
NCT03908970: Responder Rate of Investigator's Global Assesment(IGA) of Disease Severity (At Week 4): 1% OPA-15406 38.46% (95% CI 31.36 to 45.95) vs Placebo 12.64% (95% CI 8.18 to 18.36)
NCT03911401: IGA success (score 0 or 1 with at least a 2-grade improvement) at week 4: difamilast 0.3% 44.6% and 1% 47.1% vs vehicle 18.1%; p<0.001 for each dose vs vehicle. n=83, 85, 83 (Saeki 2022, Br J Dermatol).
Lebrikizumab (Ebglyss)ApprovedMonoclonal antibodyIL-13Reliable signal
NCT04178967: Percentage of Participants With an Investigator Global Assessment (IGA) Score of 0 or 1 and a Reduction ≥2 Points From Baseline to Week 16 (Baseline to Week 16): Lebrikizumab Q2W 33.2% (95% CI 27.5 to 38.9) vs Placebo 10.8% (95% CI 5.7 to 15.9)
NCT04146363: Percentage of Participants With an Investigator Global Assessment (IGA) Score of 0 or 1 and a Reduction ≥2 Points From Baseline to Week 16 (Baseline to Week 16): Lebrikizumab Q2W 43.1% (95% CI 37.1 to 49) vs Placebo 12.7% (95% CI 7 to 18.5)
Nemolizumab (Nemluvio)ApprovedMonoclonal antibodyIL-31 receptor AReliable signal
NCT03989349: Percentage of Participants With Investigator's Global Assessment (IGA) Success at Week 16: Intent-To-Treat (ITT) Population (Week 16): Initial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg 37.7% vs Initial Treatment Period (Baseline - Week 16 Predose): Placebo 26%
NCT03985943: Percentage of Participants With an Investigator's Global Assessment (IGA) Success (IGA of 0 or 1 and a More Than Equal to [>=] 2-point Reduction): Intent-To-Treat (ITT) Population (Week 16): Initial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg 35.6% vs Initial Treatment Period (Baseline - Week 16 Predose): Placebo 24.6%
Roflumilast (Zoryve)ApprovedSmall moleculePDE4Reliable signal
NCT06631170: Primary endpoint, Week 4 IGA (vIGA-AD) treatment-success rate: 31.9% with 0.15% roflumilast cream vs 6.7% with vehicle (P<0.0001)
NCT04773600: Achievement of Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) Success at Week 4 (Week 4): Roflumilast Cream 0.15% 28.9% vs Vehicle Cream 12%
Ruxolitinib (Opzelura)ApprovedSmall moleculeJAK1/2Reliable signal
NCT03745638: Percentage of Participants Who Achieved Investigator's Global Assessment - Treatment Success (IGA-TS) at Week 8 (Baseline to Week 8): VC Period: Ruxolitinib 0.75% Cream BID 50% (95% CI 43.7 to 56.3) | VC Period: Ruxolitinib 1.5% Cream BID 53.8% (95% CI 47.4 to 60) vs VC Period: Vehicle Cream BID 15.1% (95% CI 9.3 to 22.5)
NCT03745651: VC Period: Percentage of Participants Who Achieved Investigator's Global Assessment - Treatment Success (IGA-TS) at Week 8 (Baseline to Week 8): VC Period: Ruxolitinib 0.75% Cream BID 39% (95% CI 32.6 to 45.6) | VC Period: Ruxolitinib 1.5% Cream BID 51.3% (95% CI 44.6 to 58) vs VC Period: Vehicle Cream BID 7.6% (95% CI 3.5 to 14)
TapinarofApprovedSmall moleculeAryl hydrocarbon receptor, Aryl Hydrocarbon Receptor AgonistReliable signal
NCT05014568: Percent of Subjects Who Have a Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) Score of Clear or Almost Clear (0 or 1) With a Minimum 2-grade Improvement From Baseline to Week 8. Analyses Were Done Using Multiple Imputation. (Baseline to Week 8): Tapinarof Cream 45.4% vs Vehicle Cream 13.9%
NCT05032859: Percent of Subjects Who Have a Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) Score of Clear or Almost Clear (0 or 1) With a Minimum 2-grade Improvement From Baseline to Week 8. Analyses Were Done Using Multiple Imputation. (Baseline to Week 8): Tapinarof Cream 46.4% vs Vehicle Cream 18%
Tralokinumab (Adbry)ApprovedMonoclonal antibodyIL-13Reliable signal
NCT05958407: Percentage of Participants With IGA-AHE Score of 0 (Clear) or 1 (Almost Clear) (At Week 16): Tralokinumab 40% (95% CI 31.3 to 49.4) vs Placebo 10.6% (95% CI 5 to 20.9)
Upadacitinib (Rinvoq)ApprovedSmall moleculeJAK, JAK1Reliable signal
NCT03607422: EASI-75 response at week 16 (Measure Up 2): 60.1% (upadacitinib 15 mg) vs 72.9% (upadacitinib 30 mg) vs 13.3% (placebo).
NCT03569293: EASI-75 at week 16 (Measure Up 1): 70% (196/281) upadacitinib 15mg, 80% (227/285) upadacitinib 30mg, vs 16% (46/281) placebo; adjusted difference vs placebo 53.3% [46.4-60.2] and 63.4% [57.1-69.8] respectively, both p<0.0001
ADSTEMPhase 3Cell therapyautologous adipose-derived mesenchymal stem cell (AD-MSC) therapynot yet gradedNo reviewed efficacy summary in this indication
AsivatrepPhase 3Small moleculeTRPV1Reliable signal
NCT02965118: IGA success (score 0 or 1) at week 8: 36.0% asivatrep vs 12.8% vehicle (P<.001)
Baricitinib (Olumiant)Phase 3Small moleculeJAK, JAK1/2Reliable signal
NCT03334422: Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a ≥ 2 Point Improvement (Placebo, 2mg and 4mg Baricitinib) (16 Weeks): 2mg Baricitinib 10.6% | 4mg Baricitinib 13.8% vs Placebo 4.5%
NCT03334396: Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a ≥ 2 Point Improvement (Placebo, 2 mg, or 4 mg Baricitinib) (16 Weeks): 2 mg Baricitinib 11.4% | 4 mg Baricitinib 16.8% vs Placebo 4.8%
GS101Phase 3Monoclonal antibodyIL-4R-alphanot yet gradedNo reviewed efficacy summary in this indication
Jaktinib (Zepuping)Phase 3Small moleculeJAK1/2/3Partial signalNo reviewed efficacy summary in this indication
LW402Phase 3Small moleculeJAK1Partial signalNo reviewed efficacy summary in this indication
ManfidokimabPhase 3Monoclonal antibodyIL-4R-alphaPartial signalNo reviewed efficacy summary in this indication
PumecitinibPhase 3Small moleculeJAK1/2not yet gradedNo reviewed efficacy summary in this indication
QL2108Phase 3Monoclonal antibodyIL-4R-alphanot yet gradedNo reviewed efficacy summary in this indication
QLM3003Phase 3Small moleculeJAKPartial signalNo reviewed efficacy summary in this indication
RademikibartPhase 3Monoclonal antibodyIL-4R-alphaPartial signal
NCT05017480: vIGA 0/1 with a reduction of 2 points or more at week 16: rademikibart 300 mg Q2W 29.0% vs placebo 5.9%, P<0.001 (SEASIDE CHINA, Br J Dermatol 2026).
RezpegaldesleukinPhase 3Protein / enzyme therapeuticIL-2 mutein (Treg-selective)not yet gradedNo reviewed efficacy summary in this indication
SHR-1819Phase 3Monoclonal antibodyIL-4R-alphanot yet gradedNo reviewed efficacy summary in this indication
Soficitinib (ICP-332)Phase 3Small moleculeTYK2/JAK1not yet gradedNo reviewed efficacy summary in this indication
SSGJ-611Phase 3Monoclonal antibodyIL-4R-alphanot yet gradedNo reviewed efficacy summary in this indication
StapokibartPhase 3Monoclonal antibodyIL-4R-alphaReliable signal
NCT06277765: EASI-75 at week 18: 73.9% (88/119) stapokibart vs 43% (26/60) placebo; difference 30.5 percentage points (95% CI 15.3-44.3; P<0.001)
NCT05265923: EASI-75 response at week 16: 66.9% stapokibart vs 25.8% placebo (significantly higher)
TelikibartPhase 3Monoclonal antibodyIL-4R-alphanot yet gradedNo reviewed efficacy summary in this indication
TilrekimigPhase 3Multispecific antibodyIL-4/IL-13/TSLPnot yet gradedNo reviewed efficacy summary in this indication
VC005Phase 3Small moleculeJAK1, JAK1not yet gradedNo reviewed efficacy summary in this indication
ZemprocitinibPhase 3Small moleculeJAK1Reliable signal
NCT06277245: EASI-75 at Week 16: +38.1 percentage points (12 mg) and +46.4 percentage points (24 mg) vs placebo (p<0.0001); IGA 0/1 response: +30.3 percentage points (12 mg) and +31.0 percentage points (24 mg) vs placebo (p<0.0001)
AfimkibartPhase 2Monoclonal antibodyTL1Anot yet gradedNo reviewed efficacy summary in this indication
AK139Phase 2Multispecific antibodyIL-4 receptor alpha / ST2not yet gradedNo reviewed efficacy summary in this indication
BarzolvolimabPhase 2Monoclonal antibodyKITnot yet gradedNo reviewed efficacy summary in this indication
BempikibartPhase 2Monoclonal antibodyIL-7 receptor alphanot yet gradedNo reviewed efficacy summary in this indication
BFB759Phase 2Monoclonal antibodyIL-1RAPnot yet gradedNo reviewed efficacy summary in this indication
BosakitugPhase 2Monoclonal antibodyTSLPWeak signal
NCT05932654: Proportion of Patients Achieving at Least 75% Reduction in Eczema Area and Severity Index [EASI] at Week 26 (Week 26): 300 mg 94.1% (95% CI 71.3 to 99.9)
CamoteskimabPhase 2Monoclonal antibodyIL-18Partial signalNo reviewed efficacy summary in this indication
CM512Phase 2Multispecific antibodyTSLP + IL-13Weak signalFeatured results are safety only in this race
CMS-D001Phase 2Small moleculeTYK2not yet gradedNo reviewed efficacy summary in this indication
ENV-294Phase 2Small molecule—Weak signalFeatured results are safety only in this race
EVO101Phase 2Small moleculeIRAK4Partial signal
NCT05579899: Percent Change in Eczema Area and Severity Index (EASI) From Baseline to Week 8 (8 weeks): EVO101 Cream -43.5% (Standard Deviation 60.85) vs Vehicle Cream -62% (Standard Deviation 38.78) missed
EVO301Phase 2Protein / enzyme therapeuticIL-18Partial signal
NCT06723405: Placebo-adjusted improvement in EASI at Week 12: 33% (95% CI -50, -17; p<0.01)
FB825Phase 2Monoclonal antibodyCεmX domain of membrane-bound IgE (mIgE)Weak signalNo reviewed efficacy summary in this indication
FelcorekibartPhase 2Monoclonal antibodyTSLPnot yet gradedNo reviewed efficacy summary in this indication
GalvokimigPhase 2Multispecific antibodyIL-13, IL-17A, IL-17FPartial signalFeatured results are safety only in this race
GHZ339Phase 2Biologic (subtype unspecified)—not yet gradedNo reviewed efficacy summary in this indication
GIA632Phase 2Monoclonal antibodyIL-15not yet gradedNo reviewed efficacy summary in this indication
HSK44459Phase 2Small moleculePDE4Bnot yet gradedNo reviewed efficacy summary in this indication
HY209gelPhase 2Small moleculeGPCR19 / GPBAR1 (TGR5, bile acid receptor)Partial signalFeatured results are safety only in this race
IN-115314Phase 2Small moleculeJAK1not yet gradedNo reviewed efficacy summary in this indication
JNJ-95597528Phase 2Multispecific antibodyTSLP + IL-13not yet gradedNo reviewed efficacy summary in this indication
JYP0061Phase 2Small moleculeJAK1not yet gradedNo reviewed efficacy summary in this indication
KT-621Phase 2Small moleculeSTAT6Weak signalFeatured results are safety only in this race
LepzacitinibPhase 2Small moleculeJAK1/JAK3not yet gradedNo reviewed efficacy summary in this indication
LNK01004Phase 2Small moleculePan-JAKPartial signalFeatured results are safety only in this race
LT-002-158Phase 2Small moleculeIRAK4not yet gradedNo reviewed efficacy summary in this indication
LunsekimigPhase 2Antibody-derived scaffoldTSLP + IL-13not yet gradedNo reviewed efficacy summary in this indication
LutikizumabPhase 2Multispecific antibodyIL-1α/IL-1β (dual)not yet gradedNo reviewed efficacy summary in this indication
ModzatinibPhase 2Small moleculeITK and JAK3not yet gradedNo reviewed efficacy summary in this indication
MosedipimodPhase 2Small moleculeNF-kB / CCL26 pathwaynot yet gradedNo reviewed efficacy summary in this indication
Nitrosomonas Eutropha (B244)Phase 2Microbiome therapeuticlive biotherapeutic (topical ammonia-oxidizing bacterium, AOBiome/B244)Reliable signal
NCT04490109: Mean Change in Worst Itch Numeric Rating Scale (WI-NRS) (Baseline to Day 28): B244 O.D. 5.0 -2.8 score on a scale (Standard Error 0.184) | B244 O.D. 20.0 -2.8 score on a scale (Standard Error 0.184) vs Vehicle -2.1 score on a scale (Standard Error 0.18)
OlevaprubartPhase 2Monoclonal antibodyOX40Weak signalFeatured results are safety only in this race
OmpekimigPhase 2Multispecific antibodyIL-4, IL-13, IL-33Partial signal
NCT05995964: Stage 1, high-dose ompekimig vs placebo: met the primary endpoint (EASI-75 at week 16); no ompekimig figures were given (2026-03-09).
OpSCFPhase 2Monoclonal antibodyStem cell factor (SCF / KIT ligand)Partial signal
NCT06101823: Percent Change From Baseline in Eczema Area and Severity Index (EASI) at Week 16 (Baseline, Week 16): OpSCF 600 mg -71.476 percent change (Standard Error 8.6876) | OpSCF Matching-Placebo -50.992 percent change (Standard Error 8.8073)
OrismilastPhase 2Small moleculePDE4B/DPartial signal
NCT05469464: Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score at Week 16 (Baseline and Week 16): Orismilast Modified Release Tablets 20 mg BID -55.1% (Standard Error 4.89) | Orismilast Modified Release Tablets 30 mg BID -52.2% (Standard Error 5.39) | Orismilast Modified Release Tablets 40 mg BID -61.4% (Standard Error 5.02) vs Placebo Tablets BID -50.4% (Standard Error 4.98) missed
NCT02496546: In adults with mild to moderate atopic dermatitis treated twice daily for 3 weeks, total sign score at end of treatment was 5.2 (least squares mean 5.1) with orismilast cream 20 mg/g versus 6.2 (LS mean 6.3) with vehicle, a statistically significant difference (P = .014).
PF-08049820Phase 2Small moleculeSTAT6not yet gradedNo reviewed efficacy summary in this indication
PUR 0110Phase 2——not yet gradedNo reviewed efficacy summary in this indication
QLS12010Phase 2Small moleculeIRAK4not yet gradedNo reviewed efficacy summary in this indication
XKH001Phase 2Monoclonal antibodyIL-25not yet gradedNo reviewed efficacy summary in this indication
CKD-706Phase 1Monoclonal antibodyIL-4R-alphanot yet gradedNo reviewed efficacy summary in this indication
ItepekimabDiscontinuedMonoclonal antibodyIL-33not yet gradedNo reviewed efficacy summary in this indication

Large race: only the 71 furthest-along competitors are listed; 41 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(35 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Dupixent (dupilumab) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (4)
November 2026 (1)
Phase 3Atopic DermatitisActive not recruiting
Est. primary completion 2026-11 · NCT06389136 · CT.gov ↗
What to watch
December 2026 (3)
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2026-12-01 · NCT06088771 · CT.gov ↗
What to watch
Phase 2Hypereosinophilic SyndromeRecruiting
Est. primary completion 2026-12-30 · NCT06477653 · CT.gov ↗
What to watch
Phase 2AsthmaActive not recruiting
Est. primary completion 2026-12-31 · NCT05347771 · CT.gov ↗
What to watch
2027 (18)
January 2027 (2)
Phase 4AsthmaActive not recruiting
Est. primary completion 2027-01 · NCT03694158 · CT.gov ↗
What to watch
Phase 2/3Skin Inflammation, Allergic Contact DermatitisActive not recruiting
Est. primary completion 2027-01-01 · NCT05535738 · CT.gov ↗
What to watch
February 2027 (1)
Phase 4Atopic DermatitisNot yet recruiting
Est. primary completion 2027-02-07 · NCT07905547 · CT.gov ↗
What to watch
March 2027 (2)
Phase 1Locally Advanced Triple Negative Breast Cancer, TNBC - Triple-Negative Breast CancerRecruiting
Est. primary completion 2027-03-10 · NCT06637306 · CT.gov ↗
What to watch
Phase 4AsthmaActive not recruiting
Est. primary completion 2027-03-16 · NCT05097287 · CT.gov ↗
What to watch
April 2027 (2)
Phase 4AsthmaActive not recruiting
Est. primary completion 2027-04-24 · NCT06572228 · CT.gov ↗
What to watch
Phase 4Atopic DermatitisActive not recruiting
Est. primary completion 2027-04-29 · NCT05983068 · CT.gov ↗
What to watch
June 2027 (3)
Phase 4Atopic DermatitisRecruiting
Est. primary completion 2027-06 · NCT05042258 · CT.gov ↗
What to watch
Phase 3PruritusRecruiting
Est. primary completion 2027-06-02 · NCT05263206 · CT.gov ↗
What to watch
Phase 4AsthmaRecruiting
Est. primary completion 2027-06-30 · NCT06385236 · CT.gov ↗
What to watch
July 2027 (1)
Phase 4Atopic DermatitisRecruiting
Est. primary completion 2027-07 · NCT05268107 · CT.gov ↗
What to watch
October 2027 (1)
Phase 3Prurigo NodularisRecruiting
Est. primary completion 2027-10-28 · NCT06293053 · CT.gov ↗
What to watch
November 2027 (1)
Phase 2Alopecia AreataRecruiting
Est. primary completion 2027-11-30 · NCT05551793 · CT.gov ↗
What to watch
December 2027 (5)
Phase 1Eosinophilic EsophagitisEnrolling by invitation
Est. primary completion 2027-12 · NCT07358234 · CT.gov ↗
What to watch
Phase 4AsthmaRecruiting
Est. primary completion 2027-12 · NCT04743791 · CT.gov ↗
What to watch
Early phase / not applicableNon-Small Cell Lung Cancer, Immunotherapy, Neoadjuvant TherapyRecruiting
Est. primary completion 2027-12 · NCT06743581 · CT.gov ↗
What to watch
Phase 2PruritisRecruiting
Est. primary completion 2027-12-31 · NCT06226610 · CT.gov ↗
What to watch
Phase 4AsthmaRecruiting
Est. primary completion 2027-12-31 · NCT06818019 · CT.gov ↗
What to watch
2028 (9)
February 2028 (2)
Phase 4Atopic DermatitisRecruiting
Est. primary completion 2028-02-01 · NCT05858619 · CT.gov ↗
What to watch
Phase 2Nephrotic Syndrome in Children, Nephrotic Syndrome Steroid-DependentRecruiting
Est. primary completion 2028-02-28 · NCT07091175 · CT.gov ↗
What to watch
May 2028 (1)
Phase 3Atopic DermatitisNot yet recruiting
Est. primary completion 2028-05-02 · NCT07919899 · CT.gov ↗
What to watch
June 2028 (1)
Phase 3Eosinophilic EsophagitisRecruiting
Est. primary completion 2028-06-19 · NCT07112378 · CT.gov ↗
What to watch
July 2028 (1)
Phase 4Chronic Obstructive Pulmonary DiseaseRecruiting
Est. primary completion 2028-07-30 · NCT07587658 · CT.gov ↗
What to watch
December 2028 (4)
Phase 2Major Depressive DisorderRecruiting
Est. primary completion 2028-12 · NCT07908563 · CT.gov ↗
What to watch
Phase 3AsthmaEnrolling by invitation
Est. primary completion 2028-12-21 · NCT06191315 · CT.gov ↗
What to watch
Phase 4Chronic Obstructive Pulmonary DiseaseRecruiting
Est. primary completion 2028-12-23 · NCT07053423 · CT.gov ↗
What to watch
Phase 1/2Metastatic Colorectal Cancer, Liver MetastasesRecruiting
Est. primary completion 2028-12-31 · NCT07277322 · CT.gov ↗
What to watch
2029 (2)
January 2029 (1)
Phase 3AsthmaRecruiting
Est. primary completion 2029-01 · NCT07309614 · CT.gov ↗
What to watch
March 2029 (1)
Phase 2Alopecia AreataRecruiting
Est. primary completion 2029-03-31 · NCT05866562 · CT.gov ↗
What to watch
2031 (1)
June 2031 (1)
Phase 1Skin DiseasesRecruiting
Est. primary completion 2031-06-30 · NCT05649098 · CT.gov ↗
What to watch
2034 (1)
September 2034 (1)
Early phase / not applicableRhinosinusitis Chronic, Nasal PolypsRecruiting
Est. primary completion 2034-09-02 · NCT06501807 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(9)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

22 April 2026ApprovalFDA approves Dupixent for CSU in children aged 2 to 11
US, FDA · Source ↗
13 April 2026ApprovalDupixent approved in the EU for CSU in children aged 2 to 11
EU, EMA · Source ↗
April 2026FDA action dateFDA decision expected by April 2026 for CSU in children
US, FDA · Source ↗
24 March 2026ApprovalDupixent approved in Japan for bullous pemphigoid
JP, MHLW · Source ↗
27 February 2026Filing acceptedFDA accepts sBLA for Dupixent in children 2-11 with CSU
US, FDA · Source ↗
24 February 2026ApprovalFDA approves Dupixent for allergic fungal rhinosinusitis
US, FDA · Source ↗
18 April 2025ApprovalDupixent approved in the US for chronic spontaneous urticaria
US, FDA · Source ↗
18 February 2025Filing acceptedDupixent sBLA accepted by FDA for bullous pemphigoid
US, FDA · Source ↗
18 February 2025Priority reviewFDA priority review for Dupixent in bullous pemphigoid
US, FDA · Source ↗